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review of infectious complications of malig-
nant disease and in the treatment of malig-
nant disease. This is thorough and the dif-
ferent infections are arranged to stress their
relevant importance.
The self-assessment questions are compre-
hensive and, in most cases, pose valid and
relevant questions. Some questions, however,
do not appear to have a definite answer, and
it is to be hoped that the American Sub-
specialty Boards allow for discussion of con-
troversies in medical oncology in which a
simple true-or-false or multiple-choice answer
is inappropriate.
Insummary, this bookrepresents a massive
accumulation of data and information. It
cannot, however, be fully recommended,
because of its, at times, incomprehensible
styleanditslackofspacetodiscussobjectively
different treatment options available for
many of the diseases in which chemotherapy
is used.
D. CROWTHER
Molecular and Cellular Aspects of Car-
cinogen Screening Tests. Eds R. MoN-
TESANO, H. BARTSCH, L. TOMATIS (1980)
Lyons: WHO-IARC. 371 pp. US$40-00,
Sw. Fr. 60.
Some ofthe newer information on responses
of a variety of short-term tests to mutagens
and carcinogens are presented in this volume,
and it is evident that a more critical and
analytical approach to the vast amount of
data being generated is now being adopted.
Much more emphasis is now being placed on
understanding the scientific basis for the
various short-term tests. There is also a shift
of emphasis from an exclusive consideration
of tests which will detect only initiators to
those which will detect promoters and will
respond to epigenetic effects now being re-
considered as possibly involved in carcino-
genesis; this new approach being exemplified
by the contribution from Radman and his
co-workers.
The interesting section on the scientific
basis for short-term tests includes a pertinent
paper from Green (Sussex) in which the prob-
lems ofusing the Ames test as even a qualita-
tive index of carcinogenicity are discussed;
the main problem being how to define a
positive result. When attempts are made to
use even the well-validated Ames test quanti-
tatively (i.e. to attempt correlations ofmuta-
genic potency with carcinogenic potency) the
problems are compounded, and these are
lucidly discussed in this paper.
Other papers in the volume deal with inter-
laboratory reproducibility of various tests,
attempts at a classification of experimental
evidence to indicate degrees of carcinogeni-
city, and details of various international
collaborative schemes for mutagenicity and
carcinogenicity. Overall, a useful update of
progress in this rapidly expanding field.
M. Fox
Therapeutic Progress in Ovarian Cancer,
Testicular Cancer and the Sarcomas.
Ed. A. T. VAN OOSTEROM, F. M. MIUGGIA &
F. J. CLETON (1980) The Netherlands:
Leiden University. 507 pp. 124 Guilders.
In the last decade, there has been evidence
ofa gradual reduction in deaths due to cancer
in the under-45 age group. This decrease in
the younger age group can be in part attribu-
ted to the use of chemotherapy in such dis-
orders as osteosarcoma, ovarian cancer,
Hogkin's disease and acute lymphoblastic
leukaemia. Of all the newer methods of
treatmentofmalignantdisease, chemotherapy
in solid malignant tumours is one ofthe most
promising.
The 16th Boerhaave course organized by
the Faculty of Medicine, University of
Leiden, Netherlands, and the Page and
William Black Postgraduate School of Medi-
cine, Mount Sinai School of Medicine, New
York, U.S.A., was held in December 1979.
The proceedings ofthis course have now been
published by the Leiden University Press,
and the editors are to be congratulated on its
rapid production. The proceedings are a
collection of 31 original papers presented at
the course, covering ovarian cancer, testicular
cancer, osteosarcoma and the soft-tissue
sarcomas. In addition, each part ends with a
panel discussion on current and future
management.
In view ofthe acknowledged poor prognosis
of these particular tumours, this book is a
timely and important reminder that progress
in the management ofthese diseases is occur-
ring. In each section, the importance of
primary surgical treatment, accurate staging,
and the use of both adjuvant and primary
chemotherapy are stressed. Up-to-date re-BOOK REVIEWS
ports ofsingle and multiple regimes involving
both chemotherapy and radiotherapy are
given. In addition, the use ofimmunotherapy,
second-look operations, and laboratory
measurements of tumour response, such as
tumour markers and human tumour stem-cell
assays, are discussed.
The major recommendations of the panel
discussions are for centralized oncology ser-
vices to study effectively the many questions
raised. The need for collaboration between
surgeons and medical oncologists is clear, and
the prognosis for patients suffering from these
tumours is best when managed in a special-
ized oncology unit. Do not be put off by
"gross anasarca", "inimical" or progressive
"inanition" in the first few pages, the rest of
the book is well worth reading, and is an
important reference work for anyone working
in such a unit and interested in these par-
ticular tumours.
M. ELSTEIN
P. HIRSCH
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